Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Recurrence × Lomustine × Clear all

Phase

Status

Terminated 2 Completed 2 Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 9 Recurrence 1 Oligodendroglioma 1 Neoplasms 1 Neoplasm Recurrence, Local 1 Medulloblastoma 1 Lymphoma, Large B-Cell, Diffuse 1 Glioma 1 Central Nervous System Neoplasms 1 Burkitt Lymphoma 1 Brain Neoplasms 1

Interventions

venetoclax 19 Cyclophosphamide 17 pembrolizumab 15 Dexamethasone 14 Cytarabine 12 fludarabine 11 Azacitidine 10 Gemcitabine 9 pomalidomide 7 Rituximab 7 Carboplatin 7 selinexor 6 glofitamab 6 Temozolomide 6 Lenalidomide 6 Granulocyte Colony-Stimulating Factor 6 fludarabine phosphate 5 Paclitaxel 5 Oxaliplatin 5 Injections 5 Cisplatin 5 zanubrutinib 4 ruxolitinib 4 obinutuzumab 4 daratumumab 4 carfilzomib 4 Surgical Procedures, Operative 4 Nivolumab 4 Decitabine 4 Cladribine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03970447 2025-09-09

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡